Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Abstract


The article represents case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in Russian Federation. Russian oncologists’ experience has demonstrated the high efficacy and manageable safety profile of the ribociclib treatment in patients in clinical practice.

Full Text

Restricted Access

About the authors

M A Frolova

Email: drfrolova@yandex.ru

Ya I Kochetkova

V A Chubenko

Email: vchubenko@me.com

N M Volkov

F V Moiseenko

T V Garmarnik

Email: tgarmarnik@mail.ru

D M Ponomarenko

Email: ponomarenkodm@gmail.com

A E Orlov

Yu V Kostalanova

Yu Yu Makarycheva

A A Nizegorodzeva

Statistics

Views

Abstract - 13

PDF (Russian) - 1

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies